The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | Clonal Hematopoeisis of undetermined potential
Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, discusses how multiple myeloma patients with clonal hematopoeisis of undetermined potential (CHIP) are at an increased risk of cardiovascular disease and additional hematological malignancies. Dr Mouhieddine goes on to explain how immunomodulatory maintenance negates the negative effects of CHIP. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
